These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3277918)

  • 1. Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen.
    Richards RL; Hayre MD; Hockmeyer WT; Alving CR
    Infect Immun; 1988 Mar; 56(3):682-6. PubMed ID: 3277918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.
    Richards RL; Swartz GM; Schultz C; Hayre MD; Ward GS; Ballou WR; Chulay JD; Hockmeyer WT; Berman SL; Alving CR
    Vaccine; 1989 Dec; 7(6):506-12. PubMed ID: 2692333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine.
    Alving CR; Richards RL
    Immunol Lett; 1990 Aug; 25(1-3):275-9. PubMed ID: 2283158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmodium falciparum: immunogenicity of circumsporozoite protein constructs produced in Escherichia coli.
    Wirtz RA; Ballou WR; Schneider I; Chedid L; Gross MJ; Young JF; Hollingdale M; Diggs CL; Hockmeyer WT
    Exp Parasitol; 1987 Apr; 63(2):166-72. PubMed ID: 3552712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.
    Richards RL; Rao M; Wassef NM; Glenn GM; Rothwell SW; Alving CR
    Infect Immun; 1998 Jun; 66(6):2859-65. PubMed ID: 9596760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum.
    Hoffman SL; Wistar R; Ballou WR; Hollingdale MR; Wirtz RA; Schneider I; Marwoto HA; Hockmeyer WT
    N Engl J Med; 1986 Sep; 315(10):601-6. PubMed ID: 3526148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.
    Hui GS; Tam LQ; Chang SP; Case SE; Hashiro C; Siddiqui WA; Shiba T; Kusumoto S; Kotani S
    Infect Immun; 1991 May; 59(5):1585-91. PubMed ID: 2019429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen.
    Alving CR; Richards RL; Moss J; Alving LI; Clements JD; Shiba T; Kotani S; Wirtz RA; Hockmeyer WT
    Vaccine; 1986 Sep; 4(3):166-72. PubMed ID: 3532603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy.
    Fries LF; Gordon DM; Richards RL; Egan JE; Hollingdale MR; Gross M; Silverman C; Alving CR
    Proc Natl Acad Sci U S A; 1992 Jan; 89(1):358-62. PubMed ID: 1729706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of antibody responses to the circumsporozoite protein repeat region and to intact sporozoites during acute falciparum malaria.
    Brown AE; Webster HK; Pavanand K; Permpanich B; Sookto P; Sattabongkot J; Gingrich JB
    Trans R Soc Trop Med Hyg; 1989; 83(2):154-7. PubMed ID: 2692219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS.T3) and an immunomodulator (polytuftsin), and delivery through liposomes.
    Kumar P; Biswas S; Rao DN
    Microbiol Immunol; 1999; 43(6):567-76. PubMed ID: 10480553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response of humans to the circumsporozoite protein of Plasmodium falciparum: limited T cell response to the immunodominant central repeat region.
    Campbell JR; Paleologo FP; Franke ED; Ratiwayanto S; Hadiputranto H; Kurniawan L; Wistar R; Hoffman SL; Annis BA; Wasserman G
    Am J Trop Med Hyg; 1988 Sep; 39(3):232-5. PubMed ID: 2459979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a hybrid Plasmodium falciparum malaria antigen.
    Lockyer MJ; Cooper H; Tite J; Rowan W; Crowe JS
    Parasitology; 1993 Jun; 106 ( Pt 5)():451-7. PubMed ID: 8341580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity.
    Richards RL; Alving CR; Wassef NM
    J Pharm Sci; 1996 Dec; 85(12):1286-9. PubMed ID: 8961140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection.
    Webster HK; Brown AE; Chuenchitra C; Permpanich B; Pipithkul J
    J Clin Microbiol; 1988 May; 26(5):923-7. PubMed ID: 2454941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.
    Le TP; Church LW; Corradin G; Hunter RL; Charoenvit Y; Wang R; de la Vega P; Sacci J; Ballou WR; Kolodny N; Kitov S; Glenn GM; Richards RL; Alving CR; Hoffman SL
    Vaccine; 1998; 16(2-3):305-12. PubMed ID: 9607047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of Saimiri sciureus boliviensis with recombinant vaccines based on the circumsporozoite protein of Plasmodium vivax.
    Collins WE; Nussenzweig RS; Ballou WR; Ruebush TK; Nardin EH; Chulay JD; Majarian WR; Young JF; Wasserman GF; Bathurst I
    Am J Trop Med Hyg; 1989 May; 40(5):455-64. PubMed ID: 2658634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.
    Younis S; Faber BW; Kocken CHM; Remarque EJ
    BMC Immunol; 2019 Jul; 20(1):25. PubMed ID: 31362695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and efficacy trials in Aotus nancymai monkeys with model compounds representing parts of a 75-kD merozoite surface antigen of Plasmodium falciparum.
    Sharma P; Ruebush TK; Campbell GH; Richman SJ; Wilkins PP; Broderson JR; Ardeshir F; Gross M; Silverman C; Skinner JC
    Am J Trop Med Hyg; 1992 Jun; 46(6):691-707. PubMed ID: 1621894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.